Genentech

Subretinal therapy offers promise of lighter treatment burden for AMDRGX-314 gene therapy offers patients the potential for a lower treatment burden with one subretinal injection of a gene therapy delivering an anti-vascular endothelial growth factor protein.
Outcomes differ from trials with ‘real-world’ anti-VEGF therapy for DMEThe visual outcomes after anti-VEGF therapy administered to treat diabetic macular edema in the “real world” do not achieve those reported in randomized clinical trials. Eyes with better baseline visual acuity are disproportionately affected.
FDA okays biosimilar for several cancers
FDA okays biosimilar for several cancersWhile FDA has approved a handful of biosimilar drugs, the agency just approved the first biosimilar that treats a variety of types of cancer.
New treatments on the horizonEmerging therapies are showing impressive efficacy and good tolerability, according to one dermatologist.
Drug prolongs IPF life expectancy: StudyTwo recent studies demonstrate that pirfenidone (Esbriet, Genentech) prolongs life expectancy by 2.47 years for IPF patients and that Esbriet and nintedanib (Ofev, Boehringer Ingelheim) reduce the decline in lung function.
MS Group Praises New Drug Despite High Price Tag
MS Group Praises New Drug Despite High Price TagWhy a drug that costs $65,000 a year is making patient groups happy.
New Parkinson's drug, 2 others approvedFDA approved safinamide (Xadago, Newron Pharmaceuticals) tablets as an add-on treatment for patients with Parkinson’s disease. FDA also approved new treatments for classical Hodgkin lymphoma and pemphigus vulgaris, a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.
Using OCT with your diabetes patientsOCT is one of the best way to assess patients for the presence of diabetic macular edema (DME)
Why 2016 drug approvals fell
Why 2016 drug approvals fellWhile FDA approved far fewer new drugs in 2016 than 2015, the agency quickly approved novel and breakthrough therapies.
FDA approves expansion of Avastin in ovarian cancerFDA recently approved bevacizumab (Avastin, Genentech) for patients with platinum-sensitive recurrent epithelial ovarian (psOC), fallopian tube or primary peritoneal cancer.